Literature DB >> 17302245

Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.

Aylin Yilmaz1, Bo Svennerholm, Lars Hagberg, Magnus Gisslén.   

Abstract

BACKGROUND: A low-grade persisting viraemia despite long-term treatment with highly active antiretroviral therapy (HAART) has previously been demonstrated in HIV-1-infected patients. Whether ongoing viral replication also could be detected in cerebrospinal fluid (CSF) in those circumstances has not been studied before.
METHODS: Paired CSF and blood samples from 13 neurologically asymptomatic HIV-1-infected patients on stable HAART were analysed regarding HIV-1 RNA, by using a PCR assay with a detection limit of 2 copies/ml.
RESULTS: All 13 patients had HIV-1 RNA < 2 copies/ml in CSF, compared with 8/13 in plasma.
CONCLUSION: We could not demonstrate any persistent viral replication in the CSF of neurologically asymptomatic HIV-1-infected patients on effective HAART, rendering it unlikely that CSF acts as a viral reservoir in this category of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17302245

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  18 in total

1.  Effects of HIV-1 Tat on oligodendrocyte viability are mediated by CaMKIIβ-GSK3β interactions.

Authors:  Shiping Zou; Joyce M Balinang; Jason J Paris; Kurt F Hauser; Babette Fuss; Pamela E Knapp
Journal:  J Neurochem       Date:  2019-03-15       Impact factor: 5.372

2.  Antiretroviral Treatment of Acute HIV Infection Normalizes Levels of Cerebrospinal Fluid Markers of Central Nervous System (CNS) Inflammation: A Consequence of a Reduced CNS Reservoir?

Authors:  Magnus Gisslén; Peter W Hunt
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

Review 3.  Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Authors:  Francesca Ferretti; Magnus Gisslen; Paola Cinque; Richard W Price
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

Review 4.  HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment.

Authors:  Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur
Journal:  Nat Rev Neurol       Date:  2016-03-11       Impact factor: 42.937

5.  Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Authors:  Aylin Yilmaz; Richard W Price; Serena Spudich; Dietmar Fuchs; Lars Hagberg; Magnus Gisslén
Journal:  J Acquir Immune Defic Syndr       Date:  2008-02-01       Impact factor: 3.731

6.  Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.

Authors:  José L Casado; Ana Marín; Ana Moreno; Verónica Iglesias; María J Perez-Elías; Santiago Moreno; Iñigo Corral
Journal:  J Neurovirol       Date:  2014-01-14       Impact factor: 2.643

Review 7.  Antiretroviral therapy and central nervous system HIV type 1 infection.

Authors:  Richard W Price; Serena Spudich
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

8.  Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.

Authors:  Aylin Yilmaz; Arash Izadkhashti; Richard W Price; Patrick W Mallon; Marc De Meulder; Philip Timmerman; Magnus Gisslén
Journal:  AIDS Res Hum Retroviruses       Date:  2009-04       Impact factor: 2.205

9.  Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir/ritonavir (ATV/r)-containing ART: a tertiary care cohort in western India.

Authors:  Atul K Patel; Ketan K Patel; Swati Gohel; Ambuj Kumar; Scott Letendre
Journal:  J Neurovirol       Date:  2018-04-24       Impact factor: 2.643

10.  Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study.

Authors:  Annica Lindkvist; Arvid Edén; Melissa M Norström; Veronica D Gonzalez; Staffan Nilsson; Bo Svennerholm; Annika C Karlsson; Johan K Sandberg; Anders Sönnerborg; Magnus Gisslén
Journal:  AIDS Res Ther       Date:  2009-07-01       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.